Karyopharm Therapeutics | KPTI - Cost Of Sales


Karyopharm Therapeutics reported $1.48M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Abbott USD 5.3B 380M Mar/2026
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
J&J USD 8.07B 103M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 2.94B 380M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.46B 83M Mar/2026
Novartis USD 3.54B 7M Dec/2025
Pfizer USD 4.59B 1.7B Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Takeda JPY 560.54B 159.39B Mar/2026
TG Therapeutics USD 33.51M 4.63M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Xencor USD 61.66M 50.95M Jun/2025